Buy Ajanta Pharma Ltd For Target Rs. 2,130 - Yes Securities
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Result Highlights
* Strong performance across the board; India, US clocked 20% growth while India revenue rise of 23% came in as a surprise
* Africa institutional business remains volatile; company guided for Rs2.7bn in FY22 sales
* Gross margin expanded by ~400bps yoy as Q4 last year included product recall cost (mostly Ranitidine); other expenses decreased by ~18%, partly due to lower R&D. Other expenses ex‐R&D declined due to ongoing second wave that started in March. Company expects gross margin to sustain around 75% with a range of +/‐ 100bps in FY22
* R&D expenses stood at Rs390mn (5% of sales); to rise by 100bps in FY22 as FY21 was a suppressed year for research expenses
* PAT grew by 21% yoy driven by better than expected topline and margin performance
Our view:
FY22 would see rebound in domestic growth on low base (+6%) of FY21 while US would sustain 18% growth; expect some slowdown in FY23 on back of lower filings in FY21. Branded generics to maintain growth in the range of 11‐12% over FY21‐ 23.
Margin to decline in FY22 as one‐offs in the form of lack of costs in FY21 would reverse, coupled with rise in R&D to 5.8% of sales; this would result in ~450bps margin correction on FY21 base, even after assuming ~13% topline growth. Albeit, this would be a temporary phase with margin likely to inch upwards next fiscal. We raise FY22/23 revenues offset by cut in EBIDTA margin on lower gross margin leaving EPS estimates largely unchanged. BUY stays based on 25x FY23 EPS.
To Read Complete Report & Disclaimer Click Here
Please refer disclaimer at https://yesinvest.in/privacy_policy_disclaimers
SEBI Registration number is INZ000185632
Above views are of the author and not of the website kindly read disclaimer
